A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies - Concepedia

Concepedia

Publication | Open Access

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

DOI Full Paper Access

298

Citations

19

References

2009

Year

Owen A. O’Connor, A. Keith Stewart, Marcy K. Vallone, Christopher J. Molineaux, Lori Kunkel, John F. Gerecitano, Robert Z. Orlowski

Clinical Cancer Research

Abstract

This is the first clinical use of carfilzomib that shows tolerability and clinical activity in multiple hematologic malignancies using consecutive-day dosing.

References

	Year	Citations

Page 1